Inventor
FANG DOUGLAS DONG
CN14 patents
⚠️ This page may combine multiple inventors who share the name “FANG DOUGLAS DONG”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ASCENTAGE PHARMA SUZHOU CO LTD
13 patentsUS11478469B2Oct 25, 2022
Combination product of BCL-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases
ASCENTAGE PHARMA SUZHOU CO LTD2 citations71
US11452716B2Sep 27, 2022
Pharmaceutical composition and use thereof
ASCENTAGE PHARMA SUZHOU CO LTD3 citations71
US12268665B2Apr 8, 2025
Combination of immunotherapies with MDM2 inhibitors
ASCENTAGE PHARMA SUZHOU CO LTD1 citations62
US12514863B2Jan 6, 2026
Pharmaceutical combination and use thereof
ASCENTAGE PHARMA SUZHOU CO LTD0 citations61
US12194024B2Jan 14, 2025
Pharmaceutical composition of MDM2 inhibitor and use thereof for preventing and/or treating disease
ASCENTAGE PHARMA SUZHOU CO LTD0 citations61
US12370197B2Jul 29, 2025
Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
ASCENTAGE PHARMA SUZHOU CO LTD0 citations60
US12233047B2Feb 25, 2025
Pharmaceutical combination and use thereof
ASCENTAGE PHARMA SUZHOU CO LTD0 citations60
US12083136B2Sep 10, 2024
Combination of BCL-2/BCL-XL inhibitors and chemotherapeutic agent and use thereof
ASCENTAGE PHARMA SUZHOU CO LTD0 citations59
US11395815B2Jul 26, 2022
Compound for treating osteoarthritis
ASCENTAGE PHARMA SUZHOU CO LTD1 citations59
US12186304B2Jan 7, 2025
Method for treating cancer by combination of IAP inhibitor and modulator of immune checkpoint molecule
ASCENTAGE PHARMA SUZHOU CO LTD0 citations57
US11478470B2Oct 25, 2022
Combination product of Bcl-2 inhibitor or Bcl-2/Bcl-xL dual inhibitor and BTK inhibitor and use thereof in the prevention and/or treatment of diseases
ASCENTAGE PHARMA SUZHOU CO LTD0 citations57
US12287338B2Apr 29, 2025
Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway
ASCENTAGE PHARMA SUZHOU CO LTD0 citations51
US11478477B2Oct 25, 2022
Method for treating cancer by combination of FAK/ALK/ROS1 inhibitor and EGFR inhibitor
ASCENTAGE PHARMA SUZHOU CO LTD0 citations50